drugset / Trial / NCT02287818

A Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Gout

NCT02287818

Phase 2 Completed 127 enrolled TWi Biotechnology, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The study is designed to test the urate-lowering effect, safety, and tolerability of AC-201CR in an initial dosing period, followed by the addition of a ULT to test the efficacy and safety of the combination and prophylaxis of gout flares during ULT.

Timeline

Start
2014-12
Primary completion
2016-10-27
Completion
2016-10-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Diacerein Small molecule 100 mg
Background Febuxostat Small molecule 80 mg

Indications